×
About 4,186 results

ALLMedicine™ Generalized Tonic-clonic Seizures Center

Research & Reviews  927 results

Population pharmacokinetics of oxcarbazepine: a systematic review.
https://doi.org/10.1080/17512433.2021.1917377
Expert Review of Clinical Pharmacology; Chen YT, Wang CY et. al.

Apr 14th, 2021 - Oxcarbazepine is commonly used as first-line treatment for partial and generalized tonic-clonic seizures. Owing to the high pharmacokinetic variability, several population pharmacokinetic models have been developed for oxcarbazepine to explore pot...

Health-related quality of life in pediatric patients with partial onset seizures or pri...
https://doi.org/10.1016/j.yebeh.2021.107938
Epilepsy & Behavior : E&B; Trigg A, Brohan E et. al.

Apr 11th, 2021 - Study 311 (E2007-G000-311; NCT02849626) was a Phase 3, multicenter, open-label single-arm study of adjunctive perampanel oral suspension in pediatric patients (aged 4 to <12 years) with partial-onset seizures (POS) (with/without secondarily genera...

Kinetics of serum brain-derived neurotrophic factor (BDNF) concentration levels in epil...
https://doi.org/10.1016/j.eplepsyres.2021.106612
Epilepsy Research; Poniatowski ŁA, Cudna A et. al.

Mar 28th, 2021 - Epilepsy is a chronic neurological disorder characterized by the periodic and unpredictable occurrence of seizures. The serum level of brain-derived neurotrophic factor (BDNF) has been suggested to be a potential biomarker that could detect differ...

Risk of SUDEP during infancy.
https://doi.org/10.1016/j.yebeh.2021.107896
Epilepsy & Behavior : E&B; Trivisano M, Muccioli L et. al.

Mar 20th, 2021 - Risk of sudden unexpected death in epilepsy (SUDEP) in children is influenced by different factors such as etiology, seizure type and frequency, treatment, and environment. A greater severity of epilepsy, in terms of seizure frequency, seizures ty...

Social outcome and psychiatric comorbidity of generalized epilepsies - A case-control s...
https://doi.org/10.1111/epi.16870
Epilepsia Gesche J, Antonson S et. al.

Mar 18th, 2021 - To investigate social outcome and psychiatric comorbidity of patients with idiopathic/genetic generalized epilepsies (IGEs) and its subtypes (epilepsy with generalized tonic-clonic seizures alone [EGTCS], juvenile absence epilepsy [JAE], and juven...

see more →

Guidelines  2 results

Practice guideline update summary: Efficacy and tolerability of the new antiepileptic d...
https://doi.org/10.1212/WNL.0000000000005755
Neurology Kanner AM, Ashman E et. al.

Jun 14th, 2018 - To update the 2004 American Academy of Neurology (AAN) guideline for treating new-onset focal or generalized epilepsy with second- and third-generation antiepileptic drugs (AEDs). The 2004 AAN criteria were used to systematically review literature...

CARNEXIV™ (carbamazepine) Prescribing Information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206030s000lbl.pdf

CARNEXIV is indicated as replacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with the following seizure types

see more →

Drugs  1,101 results see all →

Clinicaltrials.gov  2,075 results

Topiramate - topiramate tablet, film coated-Cardinal Health
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5bc696e-040d-4d3e-b38c-9548a38fa936

May 3rd, 2021 - Topiramate is indicated for: •Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older ( 1.1); adjunctive therapy for the treatment of partial-onset seizures...

Topiramate - topiramate tablet-Aphena Pharma Solutions - Tennessee, LLC
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3b18b43c-0de2-4acf-b0d5-f1b601d496de

May 2nd, 2021 - Indications & Usage Section Topiramate is indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older (1.1); adjunctive therapy for the treatment...

Lamotrigine - lamotrigine tablet-Cardinal Health
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=beb24a4f-ab0b-435a-b60b-2b8d565ecd75

Apr 27th, 2021 - Lamotrigine is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: •Partial-onset seizures. •primary generalized tonic-clonic seizures. •generalized seizures of Lennox-Gastaut syndrome. (1.1) Epilepsy—monotherapy in pati...

Lamotrigine - lamotrigine tablet, chewable-Glenmark Pharmaceuticals Inc., USA
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50fcf452-2d21-493e-a1dd-0c6ea9ac6184

Apr 26th, 2021 - Lamotrigine tablets for oral suspension (chewable, dispersible tablets) are indicated for: Epilepsy – adjunctive therapy in patients aged 2 years and older: •partial-onset seizures. •primary generalized tonic-clonic seizures. •generalized seizures...

Levetiracetam - levetiracetam tablet, film coated-REMEDYREPACK INC.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f4a0acc-d5f5-438d-96a0-897dfebdf6e4

Apr 25th, 2021 - Levetiracetam tablet is indicated for adjunctive therapy in the treatment of: • Partial onset seizures in patients one month of age and older with epilepsy (1.1) • Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic ep...

see more →

News  81 results

Little Evidence to Support Treatments for Prevention of Sudden Unexpected Death in Epilepsy
https://www.medscape.com/viewarticle/928854

Apr 16th, 2020 - NEW YORK (Reuters Health) - More research is needed to identify effective interventions aimed at preventing sudden unexpected death in patients with epilepsy (SUDEP), according to an updated Cochrane review. SUDEP occurs with an incidence of 1 to ...

FDA Clears Epilepsy Smartwatch for Use in Children
https://www.staging.medscape.com/viewarticle/907432

Jan 8th, 2019 - The US Food and Drug Administration (FDA) has cleared for marketing the Embrace smartwatch (Empatica Inc) for seizure tracking in children as young as age 6. The Embrace smartwatch detects patterns in motion and physiological signals that may be a...

FDA Clears Epilepsy Smartwatch for Use in Children
https://www.medscape.com/viewarticle/907432

Jan 8th, 2019 - The US Food and Drug Administration (FDA) has cleared for marketing the Embrace smartwatch (Empatica Inc) for seizure tracking in children as young as age 6. The Embrace smartwatch detects patterns in motion and physiological signals that may be a...

SUDEP risk may change over time
https://www.mdedge.com/jcomjournal/article/189912/epilepsy-seizures/sudep-risk-may-change-over-time?channel=53
Erik Greb

Nov 27th, 2018 - NEW ORLEANS – Risk for sudden unexpected death in epilepsy (SUDEP) may change over time and yearly patient risk assessments are advisable, based on study results presented at the annual meeting of the American Epilepsy Society. Based on 3 years of.

FDA Expands Use of Epilepsy Drug Perampanel (Fycompa) to Younger Children
https://www.medscape.com/viewarticle/902760

Sep 30th, 2018 - The US Food and Drug Administration (FDA) has granted expanded approval of perampanel (Fycompa, Esai Inc) for the treatment of "partial-onset seizures (POS) with or without secondary generalized seizures" in patients as young as 4 years, the manuf...

see more →